Finance Watch: Venture Capital Drives Record-Breaking Year For Cell And Gene Therapies
$8.2bn In VC Deals Through Q3 Is Up 45% Year-Over-Year
Executive Summary
Private Company Edition: Recent VC financings across biopharma sectors include three major mega-rounds as Generate Biomedicines bringing in $370m, followed by $250m for Acelyrin and $125m for Chroma Medicine. Also, Treadwell raised a $91m series B and Ncardia brought in $60m-plus.